FWIW I actually consider this and MNTAs recent hiring spree as somewhat bullish. CW and co have historically been very conservative when it comes to using cash. My reading is they anticipate M-copax approval before the patent date and they also expect the drug to be rather profitable as well (including significant time as the only generic entrant).
Market Data 
Markets 
AI
